Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
RPRoyalty Pharma plc logo

Royalty Pharma plc (RPRX)

NASDAQ · Currency in USD
$63.86 ▲ +0.11 (+0.17%)
At close: Oct 23, 4:00 PM ET. Market closed.
$63.55 ▼ -0.31 (-0.49%)
Pre-market: Oct 26, 8:47 AM ET

Summary

Previous Close
$63.75
Open
$63.50
Day's Range
$63.01 – $63.93
52 Week Range
$35.92 – $64.38
Volume
4,015,551
Avg. Volume
3,115,225
Market Cap
$28.44B
Beta (5Y Monthly)
0.41
PE Ratio (TTM)
26.49
EPS (TTM)
$1.83
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
$0.94 (1.47%)
Ex-Dividend Date
Nov 13, 2026
1y Target Est
$66.50

Profile: Royalty Pharma plc

Sector
Healthcare
Industry
Medical - Pharmaceuticals
Full-time employees
100
CEO
Pablo Legorreta

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate $1.18 · Revenue est. $884.84M
DateEst.Actual
Aug 5, 2026$1.27$1.32Beat
May 6, 2026$1.21$1.30Beat
Feb 11, 2026$1.29$1.46Beat
Nov 5, 2025$0.99$1.17Beat
Aug 6, 2025$1.03$1.14Beat
May 8, 2025$0.95$1.06Beat

Analyst view

Consensus price target
$66.50 ▲ +4.1%
Range $66.00 – $67.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Similar stocks

Get free alerts on RPRX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.